Kathleen Gallagher is chief executive of Atrium, which is developing siRNA therapies for genetic cardiomyopathies. As Novartis completed its $12 billion takeover of Avidity, a new cardiology-focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results